Latest news with #Rituximab
Time of India
7 days ago
- Health
- Time of India
Costly Drug Now Free For Needy Patients With Rare Skin Disease: Doctors & NGO
Nagpur: Needy patients suffering from a rare and painful skin disorder, Autoimmune Blistering Disease, can now receive the costly drug, Rituximab, free of charge, thanks to the initiative by the Pune-based foundation, AIBDF. The announcement came during a doctors' and public awareness programme organised by the Vidarbha Dermatology Society (VDS) attended by over 200 dermatologists from across Vidarbha. "This disease is rare but deadly, and incredibly painful. Our foundation provides Rituximab injection free of cost to needy patients so they can access the best treatment," said Dr Vikrant Saoji, a senior dermatologist. Suratwala explains that he started AIBDF in memory of his late wife, Jayshree Suratwala, who tragically lost her life to this disease during the pandemic. "I wanted to ensure that no one else suffers the way she did," he said. Senior dermatologist Dr Vinit Dubey from Chandrapur sent the very first patient to AIBDF in 2023. "The patient came from a very poor family," he said, adding, "Thanks to AIBDF, my patient received the expensive medicine for free and is now doing well." Dr Asra Khumushi, president of VDS, says the initiative is a game-changer for many underprivileged patients. "I have several patients with autoimmune blistering diseases, and many come from low-income backgrounds. Steroids are often prescribed but have severe side effects. Rituximab is the most proven and effective drug. Thanks to this NGO, it's possible now for many poor patients to get this treatment," Dr Khumushi explains. Dr Nitin Barde, another dermatologist, highlighted the financial relief for patients. "The entire treatment still adds up to around Rs one lakh. The foreign version costs over Rs three lakh per dose. So, getting this drug free of cost is a huge relief for patients," he says. Jayant Hemade, co-founder of AIBDF, and a family friend of Suratwala, said the NGO has far helped 25 patients. "Until now, the foundation was entirely funded by Suratwala. But we've recently secured CSR certification and will start accepting corporate support," Hemade said. He urged both patients and dermatologists to spread the good word. VDS secretary Dr Priyanka Magia discussed the importance of early diagnosis. "Hundreds of dermatologists across Vidarbha are now aware of this service. I urge anyone experiencing symptoms of this disease to consult a dermatologist as soon as possible, because patients must go through specialists to avail this benefit," Dr Magia advises. According to doctors, AIIMS Nagpur treated 70 patients with autoimmune blistering diseases in the past three years, highlighting the growing need for accessible treatment in the region. Autoimmune Blistering Diseases (AIBDs) * Rare but potentially life-threatening skin disorders * Immune system mistakenly attacks skin and mucous membranes * Causes painful blisters, sores, infections * AIIMS Nagpur treated 70 patients in just 3 years — significant for such a rare illness * Often treated with steroids, but these have serious side effects * Rituximab is the most proven and effective drug * AIBDF now provides Rituximab free of cost to needy patients * 25 patients helped so far by the foundation
Time of India
17-06-2025
- Health
- Time of India
Transplant triumph: How science and a grandfather's gift helped save 5-year-old
Dr Chattopadhyay with his young patient and her family Dr Somnath Chattopadhyay When little Kavya came to us, she was just five years old but already carrying the heavy burden of a rare liver disease called Biliary Atresia. It's a condition in which the bile ducts inside the liver are either blocked or missing, so bile cannot drain properly. This causes the liver to get damaged and scarred over time. Sadly, without a transplant, the damage is often fatal. Kavya's story was especially close to my heart because her elder sister, Dhruvi, had battled a similar illness a decade ago. Dhruvi was four when we placed a part of her mother's liver in her tiny abdomen. She recovered successfully and was now a sprightly teen. Seeing that family's journey — the hope, struggles, the triumphs — was deeply moving. So, when Kavya needed a transplant, we knew we were fighting not just for her life but carrying forward a shared hope. Usually, when a child needs a liver transplant, one of the parents donates a part of their liver. It's a complex but common practice because blood group compatibility is simpler, and the parents are naturally the first choice. But in Kavya's case, it wasn't that simple. Her mother had already donated for Dhruvi, and her father wasn't eligible because he had fatty liver disease. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo It was then that her 70-year-old grandfather stepped in without hesitation. Now, here's where the challenge really began. Kavya's blood group was A positive, while her grandfather's was B positive — a mismatch that would typically make transplantation nearly impossible. To complicate matters further, Kavya's immune system had already developed antibodies against her grandfather's blood type. These antibodies are like tiny soldiers that recognise and attack anything foreign, including the donated liver. This mismatch and the existing antibodies could have led to immediate rejection of the transplant, risking Kavya's life. But we found a crucial piece of hope. When we measured the levels of these antibodies in Kavya's blood, they weren't as high as we had feared. This meant there was a real chance to control her immune system enough to accept the new liver. Our plan was twofold. First, we gave Kavya a medicine called Rituximab. It sounds complicated, but Rituximab works by calming down the immune cells that make those harmful antibodies. Think of it as turning down the volume on the part of the immune system that would otherwise attack the transplant. Second, we performed plasma exchange therapy. Imagine your blood as a river, with plasma as the liquid part that carries antibodies. Through plasma exchange, we 'washed out' the harmful antibodies by removing some of her plasma and replacing it with clean plasma. This process helps to clear away the soldiers ready to attack the new liver. It was a delicate dance, and every step had to be perfectly timed and executed. We knew that if even a small number of these antibodies remained, Kavya's body could reject the new liver immediately, which is often fatal. Adding to the challenge, Kavya had undergone major surgery as an infant. This had left scar tissue inside her abdomen, making the transplant surgery more complicated and riskier. Our team used advanced imaging to carefully plan how the grandfather's liver segment would fit inside Kavya's small abdomen, ensuring it wouldn't cause harm or pressure. The family's courage was remarkable throughout. Having already walked this path with their elder daughter, they understood what lay ahead. Yet, the financial strain was very real. The Jains are a modest family. Kavya's mother reached out to NGOs for support. Our hospital's trust also stepped in to help ease the burden somewhat. In Kavya's case, the parents couldn't donate. Her mom had already donated for Dhruvi, and her father had fatty liver disease. It was then that her 70-year-old grandfather stepped up Dr Chattopadhyay As for her grandfather, he underwent a series of tests — blood work, scans, heart checks — to ensure he was healthy enough to donate part of his liver. Donating a piece of your liver is a major decision. It involves surgery, pain, recovery, and risk. We make sure donors understand everything clearly and often connect them with people who have donated before. But in the Jains' case, their previous experience had prepared them emotionally and mentally. On Feb 22, Kavya was admitted. Two weeks later, the big day arrived. For ten intense hours, two surgical teams worked, connecting the liver to her blood vessels and bile ducts with utmost precision. Watching Kavya recover after surgery was incredibly rewarding. She was discharged in three weeks. Her grandfather, too, recovered well and was back to work in just seven days. Just a few decades ago, a transplant like this would have been unthinkable. Transplants across blood group barriers almost always ended in rejection. But advances in medicines like Rituximab and improved plasma exchange techniques have revolutionised what's possible. India has become a leader in living donor liver transplantation. This progress came from necessity — due to fewer deceased donors — but also from innovation, skill, and determination. Today, we perform more living donor liver transplants than any other country, often at a fraction of the cost seen in Western nations. To families facing the frightening prospect of paediatric liver disease and transplantation, my message is simple: don't lose hope. While it may feel overwhelming, these transplants have excellent success rates. Children go on to live full, vibrant lives — going to school, pursuing careers, building families. And while the idea of transplantation can be scary, it's safer today than ever before. Donors' livers regenerate, making living donation a powerful and safe gift. Dr Chattopadhyay is consultant and head of Hepato-Pancreato-Biliary Surgery and Liver Transplant at Kokilaben Dhirubhai Ambani Hospital, Mumbai. He spoke to Sharmila Ganesan Ram One step to a healthier you—join Times Health+ Yoga and feel the change
Globe and Mail
12-06-2025
- Business
- Globe and Mail
Diffuse Large B-Cell Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 70+ Companies and 75+ Therapies
DelveInsight's, ' Diffuse Large B-Cell Lymphoma Pipeline Insight 2025 ' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diffuse Large B-Cell Lymphoma pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies, key Diffuse Large B-Cell Lymphoma Companies, and future Diffuse Large B-Cell Lymphoma treatment landscapes @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report In June 2025, Genmab announced a study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. In June 2025, Mitsubishi Tanabe Pharma Corporation conducted a phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL. DelveInsight's Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment. The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others. Discover how the Diffuse Large B-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Diffuse Large B-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies Diffuse Large B-Cell Lymphoma Emerging Drugs Profile Brentuximab vedotin: Pfizer Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. THOR-707: Sanofi THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. Abexinostat: Xynomic Pharmaceuticals Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma. RNK05047: Ranok Therapeutics RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok's proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints. BMF-219: Biomea Fusion BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. ADI-001: Adicet Bio ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. The Diffuse Large B-Cell Lymphoma pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment. Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market. Get a detailed analysis of the latest innovations in the Diffuse Large B-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs Diffuse Large B-Cell Lymphoma Companies Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Diffuse Large B-Cell Lymphoma Therapies and key Diffuse Large B-Cell Lymphoma Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report Coverage- Global Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Diffuse Large B-Cell Lymphoma Therapies - Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others. Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Diffuse Large B-Cell Lymphoma drug development? Find out in DelveInsight's exclusive Diffuse Large B-Cell Lymphoma Pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Diffuse Large B-Cell Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Diffuse Large B-Cell Lymphoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Brentuximab vedotin: Pfizer Drug profiles in the detailed report….. Mid Stage Products (Phase II) THOR-707: Sanofi Drug profiles in the detailed report….. Early Stage Products (Phase I) ADI-001: Adicet Bio Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diffuse Large B-Cell Lymphoma Key Companies Diffuse Large B-Cell Lymphoma Key Products Diffuse Large B-Cell Lymphoma- Unmet Needs Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion Diffuse Large B-Cell Lymphoma Analyst Views Diffuse Large B-Cell Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Business Upturn
03-06-2025
- Business
- Business Upturn
Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors
NIJMEGEN, The Netherlands: Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose escalation and expansion BYON4228.002 clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of novel SIRPα-directed monoclonal antibody (mAb) BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors. Advertisement This press release features multimedia. View the full release here: Louis Denis, MD, Chief Medical Officer, Byondis BYON4228 is a potential best-in-class novel mAb that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. By targeting SIRPα and not CD47, BYON4228 offers selective targeting of myeloid cells and avoids disruption of other biologically meaningful CD47-dependent interactions. In preclinical studies, BYON4228 was found to potentiate the tumor killing capacity of tumor-targeting mAbs tested without the toxicity associated with CD47 agents. 'Building on strong preclinical data, we believe that there is broad potential for BYON4228 alone and in combination with tumor-targeting mAbs, checkpoint inhibitors and antibody drug conjugates and other modalities across hematological and solid tumors,' said Louis Denis, MD, Chief Medical Officer, Byondis. 'We look forward to evaluating the results of this trial to support the clinical development of BYON4228 alone and in combination with other agents and to bring a new therapeutic option to patients with high unmet medical need.' Part 1 of the BYON4228.002 trial will evaluate the safety of BYON4228 alone and in combination to determine the maximum tolerated dose (MTD), or optimal biological dose (OBD) if the MTD is not reached, and recommended combination dose regimen(s) for expansion (RDE(s)). The second part of the trial will evaluate the objective tumor response rate (ORR). The secondary objectives of this trial are safety, pharmacokinetics, immunogenicity and preliminary efficacy. The trial will be conducted at multiple sites across Europe, including the United Kingdom, Belgium and Spain. About BYON4228 BYON4228 is a novel monoclonal antibody (mAb) from Byondis' next generation immuno-oncology (IO) program that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. BYON4228 is currently being studied in two Phase 1 Clinical Trials evaluating BYON4228 alone and in combination with Rituximab in patients with Relapsed/Refractory CD20 positive B-cell Non-Hodgkin's Lymphoma (NHL) (NCT05737628) and BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors (NCT06932952). About Byondis Driven to improve patients' lives, Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics. Byondis' broad development portfolio comprises preclinical and early-stage clinical programs. The product candidates combine Byondis' expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis' expertise covers all preclinical R&D from early lead finding to production of clinical batches of the selected product candidates, which are all done in-house. The company's headquarters and state-of-the-art R&D and GMP manufacturing facilities are based in Nijmegen, the Netherlands. For more information visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Globe and Mail
21-05-2025
- Business
- Globe and Mail
Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Marginal Zone Lymphoma Pipeline Insight 2025' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Marginal Zone Lymphoma Pipeline Report to explore emerging therapies, key Marginal Zone Lymphoma Companies, and future Marginal Zone Lymphoma treatment landscapes @ Marginal Zone Lymphoma Pipeline Outlook Report Key Takeaways from the Marginal Zone Lymphoma Pipeline Report In May 2025, BeiGene announced a study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria. In May 2025, Regeneron Pharmaceuticals conducted a study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). In May 2025, Incyte Corporation organized a study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor. In May 2025, Genmab conducted a study will require visits to the sites. During the first month, participants must visit every day or every few days, depending on which trial part the participant enters. After that, participants must visit weekly, every other week, once a month, and once every 2 months, as trial participation ends. DelveInsight's Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment. The leading Marginal Zone Lymphoma Companies such as Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others. Promising Marginal Zone Lymphoma Therapies such as Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others. Discover how the Marginal Zone Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Marginal Zone Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Marginal Zone Lymphoma Clinical Trials and Studies Marginal Zone Lymphoma Emerging Drugs Tafasitamab: Incyte Corporation Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma. Amdizalisib (HMPL-689): HUTCHMED The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3'-kinase delta (PI3Kδ), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3Kδ isoform selectivity. Amdizalisib's pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin's lymphoma, including follicular lymphoma and marginal zone lymphoma. Orelabrutinib: InnoCare Pharma Orelabrutinib is a small molecule Bruton's tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL). EO2463: Enterome EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL. The Marginal Zone Lymphoma pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment. Marginal Zone Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market. Get a detailed analysis of the latest innovations in the Marginal Zone Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Marginal Zone Lymphoma Unmet Needs Marginal Zone Lymphoma Companies Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others. Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous Intravenous/ Subcutaneous NA Oral Oral/intranasal/subcutaneous Parenteral Subcutaneous Marginal Zone Lymphoma Products have been categorized under various Molecule types such as Antibody Antisense oligonucleotides Immunotherapy Monoclonal antibody Peptides Protein Recombinant protein Small molecule Stem Cell Vaccine Download DelveInsight's latest report to gain strategic insights into upcoming Marginal Zone Lymphoma Therapies and key Marginal Zone Lymphoma Developments @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspectives Scope of the Marginal Zone Lymphoma Pipeline Report Coverage- Global Marginal Zone Lymphoma Companies- Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others. Marginal Zone Lymphoma Therapies- Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others. Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Marginal Zone Lymphoma drug development? Find out in DelveInsight's exclusive Marginal Zone Lymphoma Pipeline Report—access it now! @ Marginal Zone Lymphoma Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Marginal Zone Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Marginal Zone Lymphoma – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Tafasitamab: Incyte Corporation Drug profiles in the detailed report….. Mid Stage Products (Phase II) Orelabrutinib: InnoCare Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I/II) EO2463: Enterome Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Marginal Zone Lymphoma Key Companies Marginal Zone Lymphoma Key Products Marginal Zone Lymphoma- Unmet Needs Marginal Zone Lymphoma- Market Drivers and Barriers Marginal Zone Lymphoma- Future Perspectives and Conclusion Marginal Zone Lymphoma Analyst Views Marginal Zone Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
